KRAS and neoplasm: Various factors, including histologic type, duration from symptom onset to diagnosis, tumor invasiveness, growth pattern, presence of distant metastases, P stage, extent of surgical resection, vascular/lymphatic invasion, and specific gene mutations such as programmed death-ligand 1 (PD-L1), total lesion glycolysis-primary tumor (TLG-P), and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, serve as independent prognostic indicators in PSC [3].